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Background: Normative values for fractional exhaled nitric oxide (FeNO) and the associated
co-factors are important in understanding the role of FeNO as a biomarker in airway disease.
The objective of this study is to establish reference FeNO values for youth and adult asymp-
tomatic, lifetime nonsmokers in the United States, and to describe the factors affecting these
levels.
Methods: Cross-sectional analyses of the National Health and Nutrition Examination Survey
from 2007 to 2010. The analytic sample consisted of 4718 youth and adults, ages 6e79 years,
who were lifelong nonsmokers, and free of asthma, and other respiratory conditions and symp-
toms. Loge FeNO values were used as dependent variables to test associations of demographic
and health related-covariates. Multivariable regression models were used to assess the inde-
pendent effect and covariate-adjusted contribution of the factors.
Results: The geometric mean FeNO level was 8.3, 12.1, and 16.2 ppb for males 6e11, 12e19,
and 20e79 years, and 8.4, 10.9, and 12.6 ppb for females in the corresponding age groups.
Overall, FeNO levels increased with increasing age (p < 0.001), and height (p < 0.001). In
all age groups, FeNO levels were positively associated with eosinophil counts, and with testing
in the morning. Among youths 6e11 and 12e19 years, non-Hispanics whites had lower FeNO
values than non-Hispanic blacks and Hispanic youths. No race-ethnic difference in FeNO levels
was evident for adults 20e79 years. Among adolescents and adults, FeNO levels were higher
for males than for females, controlling for all other factors.
Conclusions: These reference values and associated attributes in youths and adults are useful
in evaluating the role of FeNO in airway diseases.
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Fraction of Exhaled Nitric Oxide (FeNO) is a noninvasive
marker of airway inflammation [1]. With validated hand-
held portable electrochemical analyzers [2e7], FeNO can
be assessed more readily in research and in clinical practice
[8,9]. FeNO measurements are used by clinicians as a tool
to identify steroid responsiveness and to monitor adher-
ence to steroid therapy in some asthmatic patients [10,11].
FeNO has been demonstrated to be influenced by several
demographic, biochemical and physiologic factors. FeNO
levels have been shown to be consistently higher in persons
with respiratory conditions, including asthma as compared
to healthy people [12,13], and atopy [14e16]. Smoking is
associated with lower FeNO levels [17,18].There have been
inconsistent findings on the significance of other factors,
including age [19e22], gender [19,21e25], race-ethnicity
[26e29] height [19,22,26,30], and weight [21,26,28,29].
The contribution of food and drink [31] including nitrate-
rich foods prior to testing [32,33], the effect of environ-
mental elements, such as second hand smoke [34,35], and
diurnal variability [35e37] and FeNO have also been
explored. These studies have differed in the constellation
of factors examined, sample sizes, selection criteria, ages
of study participants and study protocol.
Despite an accumulating literature on both the scientific
and clinical role of FeNO in understanding airway inflam-
mation, reference data on the population distribution of
FeNO for children and adults in the U.S. are limited [38].
The National Health and Nutrition Examination Survey
(NHANES), a large-scale national study of the non-
institutionalized population offers the unique opportunity
to provide both FeNO reference estimates and to examine
some of the important biological and external factors that
have been associated with FeNO. See and Christiani [39]
recently presented FeNO values and thresholds from
these data showing the large variability in the population.
The primary objective of this report is to provide FeNO
values for U.S. children, adolescents and adults, free of
respiratory symptoms or disease, and lifetime nonsmokers.
A second objective is to assess the effect of age, gender,
race-ethnicity and other factors that influence FeNO levels
in this reference population.
Methods
The National Health and Nutrition Examination Survey,
conducted by the Center for Disease Control and Pre-
vention’s National Center for Health Statistics, is a cross-
sectional survey, designed to assess the health and nutri-
tional status of the civilian, non-institutionalized U.S.
population. Since its inception in the early 1970s, the Na-
tional Health and Nutrition Examination Surveys (NHANES)
have periodically monitored the respiratory health status of
the U.S. population using spirometry and other health
measures. In 2007, NHANES expanded its respiratory health
component to include FeNO measurements. Nationally
representative samples are annually selected using a com-
plex, multistage sampling design that employs probability,
stratified and cluster sampling to produce estimates for
the U.S. population. Beginning in 1999, NHANES became acontinuous survey and public use data files are released in
two year cycles. This paper is based on the combined 2005-
2006 and 2007-2008 survey cycles, the first four years that
fractional exhaled oxide (FeNO) was measured in NHANES.
During this four year period, blacks, Hispanics, persons 60
years and older and low income persons were oversampled
to produce more reliable estimates for these specific de-
mographic subgroups.
The NHANES consists of an in-person home interview
followed by a standardized physical examination in a mo-
bile examination center (MEC). The interview includes
questions on socio-demographic characteristics and other
medical conditions. Signed informed consent was obtained
by all examinees, and youths 7e11 years provided assent.
Parents or guardians provided consent for youths younger
than 16 years. The survey protocol was approved by the
National Center for Health Statistics Ethical Review Board,
Hyattsville, Maryland.
Of the 16,385 persons 6e79 years interviewed in NHANES
2007e2010, 15,938 individuals were examined. Among
these, 378 persons were ineligible for the respiratory health
examination because of reported pain or difficulty taking a
deep breath or use of supplemental oxygen during the day.
An additional 1251 persons were missing data due to
insufficient time available to complete the FeNO exam,
refusals, communication problems, equipment failure, or
other such reasons. Data were also missing for 1034 persons
who were either unable to provide a single FeNO mea-
surement after up to 10 attempts (n Z 763), or to achieve
at least two reproducible measurements (n Z 271). After,
excluding one individual with measurements above the
analyzer’s upper limit of detection (300 ppb) as an outlier,
13,274 persons had reproducible FeNO measurements.
For this study, we selected a reference sample of per-
sons free of any respiratory conditions and symptoms and
lifetime nonsmokers, based primarily on responses to
questions asked during the household interview or prior to
the FeNO testing (Online supplement Table e-1) to deter-
mine our final analytic sample of 4718 persons. The sample
for the normative FeNO study was approximately 36% of the
NHANES participants with reproducible FeNO measure-
ments. Children, adolescents and adults in the reference
population, as compared to those not selected, differed
slightly according to demographic and physical character-
istics (Online supplement Table e-2). In all three study age
groups (6e11, 12e19 and 20e79 years), participants in the
reference sample were more likely to be female than those
not selected. Adults were also slightly shorter, overall, than
those adults who were not included.Fractional exhaled nitric oxide measurements
FeNO concentration was measured in exhaled air prior to
the spirometry exam. Measurements were determined at an
expiratory flow rate of 50 ml/s using the NIOX MINO, a
portable, hand-held nitric oxide analyzer (Aerocrine AB,
Solna, Sweden). This device relies on an electrochemical
sensor to detect exhaled NO values from 5 to 300 ppb [2].
Values below 5 ppb are considered below the lower limit of
detection (LOD) of the instrument and values above
300 ppb are above its upper detection limit. The standard
FeNO(ppb)
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Figure 1 Geometric mean FeNO levels by age for US refer-
ence population, ages 6-79 years, National Health and Nutri-
tion Examination Survey, 2007e2010.
1684 D.J. Brody et al.exhalation time, as specified by the manufacturer, was 10 s
for persons at or above 130 cm in height, and 6 s for youths
below 130 cm. The testing protocol required two repro-
ducible FeNO measurements in accordance with testing
procedures recommended by the manufacturer and similar
to the American Thoracic Society/European Respiratory
Society criteria [38]. The mean of two reproducible FeNO
measurements was used as the main outcome variable.
Survey participants were coached by trained technicians
and given a total of ten attempts to achieve two repro-
ducible measurements. If the first two FeNO measurements
were both below 30 ppb and within 2 ppb of each other, or
if both were over 30 ppb and within 10% of each other, then
an exam was considered reproducible and complete.
Otherwise, up to two additional measurements were ob-
tained for reproducibility. Two measurements below the
limit of detection of the device (i.e., less than 5 ppb) were
also considered reproducible and in these cases, a value of
3.5 ppb (LOD/O2) was used as the mean. Details of the
protocol are available elsewhere [40].
Other covariates
Self-reported information on race and ethnicity was cate-
gorized as non-Hispanic white, non-Hispanic black, and
Hispanic. Persons who self-identified as any other race-
ethnicity were included in the total estimates only but are
not presented as a separate category. For the FeNO esti-
mates and percentiles for adult study population, age was
categorized as 20e39, 40e59, 60e79 years. Income was
calculated as the family income to poverty level ratio
(FIPR) by dividing family income by a poverty threshold
specific for family size and year of exam, and then cate-
gorized using a cut point of FIPR <1.3 for the lowest income
group. Weight (kg) and height (cm), measured during the
examination were also used to calculate body mass index
(weight kg./height m2). Although blood eosinophil count
500 cells/mL was initially used to exclude persons from
the reference sample, counts of less than 500 cells/mL were
further assessed as a covariate categorized as 200 cells/
mL and <200 cells/mL. Other covariates were time of testing
(morning, afternoon, or evening session), reported family
history of asthma, and exposure to second hand smoke in-
side the home. Responses to pre-examination questions
(ages 12e79 years only) on factors reported to effect FeNO
prior to the measurements were also assessed, including
strenuous exercise in the last hour, food or drink in the last
hour, and consumption of nitrate-rich meats or vegetables
in the last 3 h.
Data analysis and statistical methods
Statistical analyses were performed using SAS, version 9.2
(SAS Institute, Cary, NC) and SAS-callable SUDAAN version
10.0 (Research Triangle Institute, Research Triangle Park,
NC) was used to account for the complex survey design. All
analyses were conducted using the NHANES examination
weights to account for differential probabilities of selec-
tion, non-coverage and nonresponse, and to obtain esti-
mates representative of the civilian, non-institutionalized
U.S. population. Standard errors were estimated by TaylorSeries Linearization using SUDAAN to account for the sam-
ple design. The LOESS procedure (Proc SGPLOT) in SAS was
used to create the smoothed graphs for-age trends. This
procedure uses locally weighted polynomial regression to fit
a smoothed line. Trends in age were tested using
Satterthwaite-adjusted F statistics from linear regressions.
FeNO values are skewed; therefore, they were loge-trans-
formed to normalize the distribution of FeNO measure-
ments. Loge-transformed FeNO values were used to
calculate geometric means and standard errors by age
group, gender and race-ethnicity. Selected percentiles for
FeNO were also calculated.
The loge FeNO values were also used as dependent var-
iables to test associations of demographic and health
related-covariates previously shown to be associated with
FeNO. Associations were first tested using the Student t-
test and simple linear regression. Multivariable regression
models were used to assess the independent effect and
covariate-adjusted contribution of the factors. Main effects
were first tested and then two-way interactions were
tested one at a time adding the interaction term to the
original model. Interaction terms were not included in the
final models because they did not significantly add to the fit
of the models. Covariates that were independently associ-
ated with FeNO at a p 0.05 were considered for the final
linear regression models. Separate regression analyses were
performed for age groups 6e11 years, 12e19 years, and 20
years and older. The final models included persons in the
three major race-ethnic subgroups.
Results
We found a significant linear trend (p < 0.001) of increasing
FeNO level with increasing age overall for both men and
women of all ages (Fig. 1). The age relationship was also
present in the three race-ethnic subgroups (Fig. 2).
Table 1 presents the geometric mean, standard error,
median, and 2.5th, 10th, 25th, 75th, 90th, and 97.5th
percentile FeNO values by gender and race-ethnicity for
three major age groups. The percent of persons with FeNO
FeNO(ppb)
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Figure 2 Geometric mean FeNO levels by race-ethnicity and
age for US reference population, ages 6e79 years, National
Health and Nutrition Examination Survey, 2007e2010.
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also shown. For children 6e11 years, the overall geometric
mean FeNO value was 8.3 ppb (SE Z 0.2), and was 8.3 ppb
(SE Z 0.3) and 8.4 ppb (SE Z 0.2), for boys and girls,
respectively One-fifth of children 6e11 years had FeNO
levels below the detection limit (5 ppb).
Among youths 12e19 years, geometric mean FeNO value
was 12.1 ppb, (SEZ 0.4); 13.5 ppb (SEZ 0.6) for boys, and
10.9 ppb (SE Z 0.4) for girls. Among adults 20e79, the
geometric mean FeNO was 14.1 ppb (SE Z 0.2), and
approximately 4 ppb higher in males than in females. The
90th percentile was approximately twice that of the me-
dian. By finer age categories (Online supplement, Table e-
3), geometric mean FeNO levels were lowest among
20e39 year olds (12.9 ppb) and highest among 60e79 year
olds (17.3 ppb).
Table 2 provides estimated geometric mean FeNO levels
by baseline characteristics, and other possible confounders,
in each of three age groups. By gender, both female ado-
lescents and female adults had lower geometric mean FeNO
levels than their male counterparts; although this difference
was not seen in younger children. Differences in geometric
mean values for FeNO varied with non-Hispanic blacks having
higher values as compared to non-Hispanic whites, for the
children and adolescents, but not for the adults. Geometric
mean FeNO values increased with height (p < 0.001) within
all three age groups (see also, Fig. 3). Geometric mean FeNO
varied by time of day of FeNO testing across the age groups,
with higher values found among those persons tested during
the morning sessions (8:30 AMe12:00 PM) as compared with
those tested in the afternoon and evening sessions. Adults
who reported having food or a beverage an hour before the
exam had slightly, although significantly, lower geometric
mean FeNO values (13.9 ppb) than those who did not eat or
drink (14.5 ppb), as did those who reported eating nitrate-
rich vegetables up to 3 h before the exam (16.4 vs
14.0 ppb). Among children and adults, geometric mean FeNO
levels were higher among persons with blood eosinophil
counts greater than or equal to 200 but less than 500 cells/mL
as compared to those with less than 200 cells/mL. There wasno evidence of any significant difference in FeNO levels with
BMI, second-hand smoke exposure, or family history of
asthma in any age group.
The coefficients from multiple linear regression models
of the logln of FeNO, stratified by age group, are shown in
Table 3. Only the covariates that remained significant in
either model are shown. Due to the colinearity of age and
height in children and adolescents, age was not included in
the models for these age groups. Among adults, FeNO levels
increased with increasing age. Height, blood eosinophil
count and time of exam session were independent pre-
dictors of FeNO values in all age group-specific models. The
size and the direction of the coefficients were consistent
across all models, but the statistical significance varied by
age group. Race-ethnicity (non-Hispanic black and Hispan-
ic) were associated with higher FeNO levels among children
and adolescents but not adults, whereas gender (male) was
associated with higher FeNO among adolescents and adults
but not among children.Discussion
In the present study we have provided FeNO geometric
means and selected percentile estimates and have examined
anthropologic, physiologic and other external and
examination-related factors related to FeNO levels. Unlike
the recent report of normal values and thresholds also based
on the NHANES [39] we have limited our analyses of the
population sample to lifelong nonsmoking healthy adults and
children. Nonetheless, our results in an asymptomatic sam-
ple showed a similar wide range of variability of FeNO levels
across demographic groups. Results of our multivariable
regression modeling which included the significant de-
mographic and physiologic predictors also explained little of
the variability in our healthy, general population.
Differences in FeNO analyzers and measurement pro-
tocols, sample sizes, age groups and race-ethnic constitu-
encies, and exclusionary criteria of reference populations
in other studies make it difficult to compare findings. For
the youngest children, 6e11 years, our geometric mean of
8.3 ppb was lower than that found in a 2009 study of Cali-
fornia school children [27] (10.9 ppb), and closer to the
mean reference value (8.7 ppb) for healthy children in Italy
[30], ages range 6e15 years. Few normative studies of FeNO
levels have focused on the adolescent age group aged
12e19 years where we found a higher geometric mean
FeNO level among young men (12.1 ppb) compared with
young women, (10.9 ppb). A study of 11e18-year-old Hong
Kong school children [28] also found gender differences
among healthy controls although mean FeNO levels were
higher. The geometric mean of our adult population
(14.1 ppb) was similar to the geometric mean of 13.9 ppb
found by Karrasch et al. [17], and slightly lower than other
normative adult studies. In a New Zealand study [22] of
25e75-year-olds, researchers found a geometric mean level
of 17.9 ppb and a large study of 1131 adults in a general
population in Sweden [19] reported a mean of 16.6 ppb
among healthy adults.
A major finding of our study was that among youths
(6e19 years) FeNO levels were higher in non-Hispanic
blacks and Hispanics compared to non-Hispanic whites, a
Table 1 Weighted geometric means and selected percentiles of FeNO measurements (ppb), Reference population by gender
and race-ethnicity for three age groups: NHANES 2007e2010.





2.5th 10th 25th 50th 75th 90th 97.5th
6e11 Both Allb 1091 8.3 (0.2) 20.5 c c 5.3 7.8 11.5 18.6 43.3
Hispanic 446 8.6 (0.3) 17.5 c c 5.7 8.2 11.7 19.3 36.0
Non-Hispanic white 372 7.6 (0.3) 22.8 c c 5.1 7.3 10.7 15.4 29.0
Non-Hispanic black 216 10.7 (0.7) 17.1 c c 6.1 9.0 17.4 33.7 60.5
Boys Allb 523 8.3 (0.3) 22.0 c c 5.2 7.6 11.1 19.5 44.0
Hispanic 223 8.7 (0.4) 17.7 c c 5.8 8.2 11.4 20.5 41.2
Non-Hispanic white 183 7.4 (0.4) 25.5 c c c 6.8 10.0 16.3 40.4
Non-Hispanic black 91 10.4 (1.1) 19.4 c c 6.1 8.9 17.3 33.0 53.3
Girls Allb 568 8.4 (0.2) 19.2 c c 5.4 7.9 11.9 17.4 37.1
Hispanic 223 8.5 (0.5) 17.3 c c 5.6 8.1 12.0 17.7 31.3
Non-Hispanic white 189 7.8 (0.3) 20.2 c c 5.3 7.7 11.0 14.9 23.9
Non-Hispanic black 125 11.0 (0.6) 15.3 c c 6.1 9.0 17.3 34.8 61.5
12e19 Both Allb 913 12.1 (0.4) 5.4 c 5.8 8.0 11.1 16.5 26.9 51.6
Hispanic 356 12.1 (0.6) 6.8 c 5.5 7.6 11.6 16.7 28.7 70.1
Non-Hispanic white 286 11.2 (0.4) 6.0 c 5.8 7.8 10.5 14.7 22.8 40.1
Non-Hispanic black 224 14.7 (0.7) 1.8 4.3 6.5 9.0 13.1 21.5 39.6 65.1
Male Allb 444 13.5 (0.6) 5.4 c 6.2 8.9 12.5 19.5 33.2 55.4
Hispanic 180 13.9 (0.9) 4.6 c 6.0 8.7 12.8 18.4 33.9 72.0
Non-Hispanic white 141 12.5 (0.9) 6.9 c 5.9 8.7 11.6 16.8 27.7 41.1
Non-Hispanic black 104 16.0 (0.9) 2.1 4.0 7.7 10.0 13.8 24.8 37.8 63.0
Female Allb 469 10.9 (0.4) 5.4 c 5.7 7.4 10.0 14.4 20.8 47.1
Hispanic 176 10.6 (0.9) 9.1 c 4.0 6.7 9.9 14.9 21.5 39.0
Non-Hispanic white 145 10.2 (0.4) 5.3 c 5.8 7.4 9.7 13.3 18.2 32.0
Non-Hispanic black 120 13.8 (0.9) 1.6 4.1 5.9 8.4 12.3 18.3 41.3 65.5
20e79 Both Allb 2714 14.1 (0.2) 2.8 c 6.8 9.5 13.9 19.7 27.9 43.7
Hispanic 996 13.6 (0.4) 4.2 c 6.7 9.2 13.1 19.2 27.0 48.2
Non-Hispanic white 1090 14.1 (0.3) 2.6 c 6.8 9.7 14.1 19.6 27.3 38.9
Non-Hispanic black 489 13.9 (0.5) 3.7 c 6.5 8.6 13.4 19.7 30.9 55.0
Male Allb 1148 16.2 (0.4) 2.0 5.5 7.9 10.9 15.9 23.0 32.4 50.0
Hispanic 397 15.6 (0.5) 3.0 c 7.8 10.6 15.9 21.3 29.4 49.5
Non-Hispanic white 472 16.2 (0.6) 1.8 5.8 8.3 11.2 16.0 22.8 31.5 44.9
Non-Hispanic black 216 15.1 (0.9) 3.4 c 6.6 8.9 14.0 21.8 38.4 81.4
Female Allb 1566 12.6 (0.2) 3.5 c 6.4 8.6 12.6 17.5 23.8 35.3
Hispanic 599 12.1 (0.4) c 6.2 8.3 11.6 16.6 23.9 42.3
Non-Hispanic white 618 12.7 (0.3) 3.2 c 6.4 8.7 12.8 17.6 23.2 33.6
Non-Hispanic black 273 13.2 (0.5) 3.9 c 6.4 8.5 12.9 18.4 28.5 43.5
a LOD Z Limit of detection: 5 ppb.
b Includes race-ethnicity groups not shown separately.
c Below the limit of detection.
1686 D.J. Brody et al.relationship not seen in adults. There is limited data on
race-ethnic differences for FeNO in any age group. Kovesi
et al. [26] found higher FeNO levels in African-Canadian
children than among white children. Linn et al. [27],
found that FeNO levels were higher among young Hispanic
and African-Americans children compared with non-
Hispanic white children, and, Asian children had the high-
est FeNO levels of any race or ethnic subgroup in their
study. FeNO values in Chinese children [28,29] were re-
ported to be higher than among healthy non-Asians of other
studies. While we did not observe race-ethnic differences
among adults, studies of Korean adults [21] and of healthy,
nonsmoking African Americans adults [23] both noted
higher FeNO levels for their subjects compared with pre-
viously published studies of white adults, but neither ofthese study included subjects of other race or ethnicities.
Our findings of FeNO differences by race-ethnicity only
among youths are provocative. In a sensitivity analysis of
youths that we conducted prior to any exclusions based on
asthma or smoking status, young non-Hispanic blacks
consistently showed higher mean FeNO levels as compared
with young non-Hispanic whites. Thus, it is unlikely that the
ethnic difference is due to chance. Although misclassifica-
tion of our participants in our reference population is
possible we would not expect a systematic bias in the
reporting of symptoms by race-ethnicity. Our criteria for
defining our reference population were stringent and
methodical; our exclusion criteria were based on statistical
testing of respiratory disease and related symptoms and
conditions reported in the literature to be related to FeNO.
Table 2 Geometric FeNO (ppb) by baseline characteristics of reference population for three age groups, National Health and
Nutrition Examination Survey (2007e2010).
Age groups 6e11 years 12e19 years 20e79 years
n Geometric mean (SE) n Geometric mean (ppb) n Geometric mean (ppb)
Characteristic
Gender
Male (Ref) 523 8.3 (0.3) 444 13.5 (0.6) 1148 16.2 (0.4)
Female 568 8.4 (0.2) 469 10.9 (0.4)y 1566 12.6 (0.2)y
Race-Ethnicity
Non-Hispanic White (Ref) 372 7.6 (0.3) 286 11.2 (0.4) 1090 14.1 (0.3)
Hispanic 446 8.6 (0.3)y 356 12.1 (0.6) 996 13.6 (0.4)
Non-Hispanic Black 216 10.7 (0.7)y 224 14.7 (0.7)y 489 13.9 (0.5)
Height
<25th percentile 281 6.3 (0.3)y 241 10.7 (0.7)y 863 12.6 (0.3)y
25the50th percentile 258 8.3 (0.4)y 245 11.5 (0.4)y 672 13.3 (0.3)y
50the75th percentile 290 9.3 (0.5) 209 12.2 (0.8) 633 14.4 (0.5)y
>75th percentile (Ref) 262 9.8 (0.5) 207 14.3 (0.8) 535 16.4 (0.6)
BMI
Underweight or normal (Ref) 716 8.1 (0.2) 583 12.0 (0.4) 739 13.7 (0.4)
Overweight 165 9.3 (0.5)y 145 12.3 (0.8) 956 14.5 (0.3)
Obese 210 8.4 (0.5) 171 12.3 (0.5) 1007 14.0 (0.3)
Exercised strenuously last houra
Yes 24 10.6 (1.1) 26 15.4 (2.0)
No (Ref) 889 12.1 (0.4) 2688 14.1 (0.2)
Ate or drank last houra
Yes 588 12.2 (0.4) 1590 13.9 (0.3)
No (Ref) 325 11.7 (0.4) 1124 14.5 (0.3)
Ate nitrate-rich vegetables last 3 ha
Yes 44 12.7 (1.8) 133 16.4 (1.1)
No (Ref) 869 12.0 (0.3) 2580 14.0 (0.3)y
Ate nitrate-rich meats last 3 ha
Yes 41 12.9 (1.5) 88 14.3 (1.1)
No (Ref) 872 12.0 (0.4) 2626 14.1 (0.2)
Exam Session attended
Morning (Ref) 443 9.0 (0.4) 431 12.5 (0.6) 1292 14.1 (0.3)
Afternoon 405 8.1 (0.3) 306 12.8 (0.6) 929 14.8 (0.4)
Evening 243 7.7 (0.4)y 176 9.9 (0.4)y 493 13.0 (0.4)y
Second hand smoke exposure
Yes 162 7.9 (0.6) 117 12.0 (0.6) 135 14.5 (0.9)
No (Ref) 921 8.5 (0.2) 793 12.1 (0.4) 2564 14.1 (0.2)
Family history of asthma
Yes 261 8.7 (0.4) 211 11.8 (0.7) 363 14.5 (0.5)
No (Ref) 813 8.3 (0.2) 696 12.2 (0.4) 2312 14.1 (0.2)
Eosinophil count
<200 cells/mL blood 445 7.2 (0.3) 448 10.8 (0.4) 1433 13.1 (0.2)
200< –500 cells/mL blood (Ref) 471 8.7 (0.3)y 373 13.4 (0.6)y 1142 15.8 (0.3)
yp < 0.05.
a Respiratory health pre-examination question: ages 12e79 years only.
Reference values and factors associated with ENO: U.S. 1687However, other factors that we did not investigate may
differentially affect children by race-ethnicity. Further-
more, race-ethnicity may serve as a proxy for other un-
measured factors, biological or environmental also related
to FeNO [8,41]. Nonetheless, the differences we observed
in FeNO levels by race-ethnicity are novel and suggest the
need for further investigation.
We showed, overall, in our sample of persons 6e79 years
of age, that FeNO levels increased linearly with age. In
separate sensitivity analyses that we performed, age washighly correlated with height, especially among young
children. In our models, age, height and gender all
remained independent predictors of FeNO in adults. Other
studies with adults with a broad age range [17,19] have
reported higher FeNO among persons in older age groups, as
have studies of children and adolescents [20,29,34]. In
contrast, Kovesi et al. [26], in a sample of Canadian school
children 9e12 years of age, and Baraldi et al. [30], in a
small sample of Italian school children 6e15 years of age,
found that age was not an independent predictor of FeNO.
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Figure 3 Geometric mean FeNO levels by height (cm) for
three age groups, US reference population, National Health
and Nutrition Examination Survey, 2007e2010.
1688 D.J. Brody et al.Gender was an independent predictor in adolescents and
adults, but not for the children. Gender has also been
widely reported as a determinant of FeNO with higher
levels among males compared with females, especially in
studies of adults [20,22e25,42,43], however; there are
inconsistent results with some studies showing no associa-
tion of FeNO with gender [19,26,30,35,44].
Height was a significant predictor of FeNO levels in all
three age groups, independent of all other covariates,
including gender. This confirms results published in other
studies of youths [35,45e47] and adults [19,42,44,48,49],
where FeNO values have been shown to be higher in tallerTable 3 Coefficients from Univariate and Multiple Regression M
lation, National Health and Nutrition Examination Survey, 2007e
Models Univariate regression model





Age (per year) 0.09y 0.02
Height (per 10 cm) 0.14y 0.11y












* <0.05, y <0.01.persons. On the contrary, several studies have reported
that height was not an independent predictor of FeNO
[27,30,34,43]. Age ranges and sample sizes may not have
been adequate to fully investigate the relationship. We also
examined BMI and FeNO levels but did not find any
association.
We also examined several external factors previously
shown to be related to FeNO including time of testing,
second hand smoke exposure, recent ingestion of food or
drink, including nitrate-rich foods, and heavy physical ex-
ercise prior to the testing. The results, however, showed no
influence of any of these factors except for the time of day
of the measurement where we found that FeNO levels were
consistently lower in persons tested in the evening sessions.
As with other factors we examined, findings from other
studies on FeNO levels and diurnal variability are equivocal.
In a study of circadian rhythms by Antosova and colleagues
[36], FeNO levels peaked in the AM, and Pijnenburg et al.
[50] found geometric mean levels 14% higher in the morning
as compared to afternoon levels. In two different studies of
asthmatic youth [37,51] there was no diurnal or day- to- day
variation, and a study of children in Taiwan [29] showed
FeNO measurements were lower in the mornings compared
to afternoon values. The diurnal variability demonstrated in
our study suggests that time of day should be considered for
any serial monitoring of FeNO levels.
Results from our multiple linear regression models
showed a significant relationship between FeNO and pe-
ripheral blood eosinophil count, an association that has not
been previously examined in a large reference population.
Despite the exclusion of NHANES participants with counts
over 500 cells/mL blood from the study sample, eosinophil
count remained the strongest predictor in our models
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Reference values and factors associated with ENO: U.S. 1689sensitivity analyses that excluded persons with eosinophil
counts >300 cells/mL blood yielded similar results among
adolescents and adults. In studies of asthma, the percent of
eosinophil in induced sputum is highly correlated with
airway inflammation [1]. Strunk et al. [52] found a relation
between FeNO and peripheral blood eosinophil among mild
to moderate asthmatic children and the association has
been observed in asymptomatic atopic subjects, as well
[53,54]. Our finding that usual peripheral blood eosinophil
counts were associated with FeNO levels suggests the
presence of mild eosinophilic inflammation in the absence
of respiratory symptoms or allergic co-morbidities, and
warrants further examination. Allergic sensitization, known
to significantly influence the eosinophilic count and FeNO
levels [55], was not assessed in NHANES.
Several strengths and deficiencies of this analysis should
be considered. NHANES has many methodological strengths
including being a nationally representative cross-sectional
sample, high response rates, the over-sampling of older
persons and race/ethnic subgroups, and most importantly
its standardized, quality control protocol for data collec-
tion. As such it is an ideal vehicle for population-based
estimation to establish reference ranges for laboratory
measures such as FeNO. There are, however, limitations to
the current study. First, the FeNO analyzer that we used
was a portable, hand-held device that did not require the
degree calibration of the electro-chemical analyzers.
However, the NIOX-MINO does not have the precision at
the lower levels of detection [2] compared to other FeNO
analyzers. While nearly one-fifth of the measurements for
the youth 6e11 years had levels below the limit of detec-
tion, these lower levels likely reflect a healthy constituency
of the sample that resulted after the exclusion of most
known respiratory conditions. Second, in assembling the
reference sample of persons for analysis, it was not possible
to evaluate all of the factors that are either known or hy-
pothesized to affect FeNO measurements [8]. The NHANES
population in this report was derived so as to eliminate all
persons with airway diseases or respiratory symptoms,
cough and cold within 7 days of the examination, as well as
any current or former smokers. However persons with
atopic disorders, such as chronic rhinosinustis, urticarial or
eczema could not be excluded because NHANES 2007e10
did not obtain questionnaire, laboratory (i.e., serum IgE) or
allergy skin test reactivity data in these areas. Data also
were not collected on other medical conditions that
conceivably might influence FeNO levels such as pulmonary
hypertension. Higher levels of FeNO have been well-
associated with atopy and allergic rhinitis [14,42]. Some
of the higher values seen in our reference population may
be a result of atopic or allergic sensitivity in the absence of
reported respiratory symptoms or diagnosed asthma.Conclusions
We have established FeNO reference values for U.S. chil-
dren, adolescents and adults, free from respiratory symp-
toms, and lifetime nonsmokers, and have assessed the
association of demographic characteristics and other co-
factors with FeNO levels. Findings from our study demon-
strate the variability of FeNO in the U.S. population, andthe important factors that affect FeNO level, including age,
height, gender, race-ethnicity, eosinophil count, as well as
the time of day of the FeNO exam.Ethics
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